#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Family-based case-control study of homotopic connectivity in first-episode, drug-naive schizophrenia at rest Family-based case-control design is rarely used but powerful to reduce the confounding effects of environmental factors on schizophrenia.
1-1	0-12	Family-based	_
1-2	13-25	case-control	_
1-3	26-31	study	_
1-4	32-34	of	_
1-5	35-44	homotopic	_
1-6	45-57	connectivity	_
1-7	58-60	in	_
1-8	61-74	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-9	75-76	,	_
1-10	77-87	drug-naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-11	88-101	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-12	102-104	at	_
1-13	105-109	rest	_
1-14	110-122	Family-based	_
1-15	123-135	case-control	_
1-16	136-142	design	_
1-17	143-145	is	_
1-18	146-152	rarely	_
1-19	153-157	used	_
1-20	158-161	but	_
1-21	162-170	powerful	_
1-22	171-173	to	_
1-23	174-180	reduce	_
1-24	181-184	the	_
1-25	185-196	confounding	_
1-26	197-204	effects	_
1-27	205-207	of	_
1-28	208-221	environmental	_
1-29	222-229	factors	_
1-30	230-232	on	_
1-31	233-246	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-32	247-248	.	_

Text=Twenty-eight first-episode, drug-naive patients with schizophrenia, 28 family-based controls (FBC), and 40 healthy controls (HC) underwent resting-state functional MRI.
2-1	249-261	Twenty-eight	_
2-2	262-275	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-3	276-277	,	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-4	278-288	drug-naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-5	289-297	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-6	298-302	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-7	303-316	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-8	317-318	,	_
2-9	319-321	28	_
2-10	322-334	family-based	http://maven.renci.org/NeuroBridge/neurobridge#CaseControlStudy
2-11	335-343	controls	http://maven.renci.org/NeuroBridge/neurobridge#CaseControlStudy
2-12	344-345	(	http://maven.renci.org/NeuroBridge/neurobridge#CaseControlStudy
2-13	346-349	FBC	http://maven.renci.org/NeuroBridge/neurobridge#CaseControlStudy
2-14	350-351	)	http://maven.renci.org/NeuroBridge/neurobridge#CaseControlStudy
2-15	352-353	,	_
2-16	354-357	and	_
2-17	358-360	40	_
2-18	361-368	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-19	369-377	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-20	378-379	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-21	380-382	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-22	383-384	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-23	385-394	underwent	_
2-24	395-408	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-25	409-419	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-26	420-423	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-27	424-425	.	_

Text=Voxel-mirrored homotopic connectivity (VMHC), receiver operating characteristic curve (ROC), and support vector machine (SVM) were used to process the data.
3-1	426-440	Voxel-mirrored	_
3-2	441-450	homotopic	_
3-3	451-463	connectivity	_
3-4	464-465	(	_
3-5	466-470	VMHC	_
3-6	471-472	)	_
3-7	473-474	,	_
3-8	475-483	receiver	_
3-9	484-493	operating	_
3-10	494-508	characteristic	_
3-11	509-514	curve	_
3-12	515-516	(	_
3-13	517-520	ROC	_
3-14	521-522	)	_
3-15	523-524	,	_
3-16	525-528	and	_
3-17	529-536	support	_
3-18	537-543	vector	_
3-19	544-551	machine	_
3-20	552-553	(	_
3-21	554-557	SVM	_
3-22	558-559	)	_
3-23	560-564	were	_
3-24	565-569	used	_
3-25	570-572	to	_
3-26	573-580	process	_
3-27	581-584	the	_
3-28	585-589	data	_
3-29	590-591	.	_

Text=Compared with the FBC, the patients showed lower VMHC in the precuneus, fusiform gyrus/cerebellum lobule VI, and lingual gyrus/cerebellum lobule VI.
4-1	592-600	Compared	_
4-2	601-605	with	_
4-3	606-609	the	_
4-4	610-613	FBC	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-5	614-615	,	_
4-6	616-619	the	_
4-7	620-628	patients	_
4-8	629-635	showed	_
4-9	636-641	lower	_
4-10	642-646	VMHC	_
4-11	647-649	in	_
4-12	650-653	the	_
4-13	654-663	precuneus	_
4-14	664-665	,	_
4-15	666-674	fusiform	_
4-16	675-691	gyrus/cerebellum	_
4-17	692-698	lobule	_
4-18	699-701	VI	_
4-19	702-703	,	_
4-20	704-707	and	_
4-21	708-715	lingual	_
4-22	716-732	gyrus/cerebellum	_
4-23	733-739	lobule	_
4-24	740-742	VI	_
4-25	743-744	.	_

Text=The patients exhibited lower VMHC in the precuneus relative to the HC.
5-1	745-748	The	_
5-2	749-757	patients	_
5-3	758-767	exhibited	_
5-4	768-773	lower	_
5-5	774-778	VMHC	_
5-6	779-781	in	_
5-7	782-785	the	_
5-8	786-795	precuneus	_
5-9	796-804	relative	_
5-10	805-807	to	_
5-11	808-811	the	_
5-12	812-814	HC	_
5-13	815-816	.	_

Text=ROC analysis exhibited that the VMHC values in these brain regions might not be ideal biomarkers to distinguish the patients from the FBC/HC.
6-1	817-820	ROC	_
6-2	821-829	analysis	_
6-3	830-839	exhibited	_
6-4	840-844	that	_
6-5	845-848	the	_
6-6	849-853	VMHC	_
6-7	854-860	values	_
6-8	861-863	in	_
6-9	864-869	these	_
6-10	870-875	brain	_
6-11	876-883	regions	_
6-12	884-889	might	_
6-13	890-893	not	_
6-14	894-896	be	_
6-15	897-902	ideal	_
6-16	903-913	biomarkers	_
6-17	914-916	to	_
6-18	917-928	distinguish	_
6-19	929-932	the	_
6-20	933-941	patients	_
6-21	942-946	from	_
6-22	947-950	the	_
6-23	951-957	FBC/HC	_
6-24	958-959	.	_

Text=However, SVM analysis indicated that a combination of VMHC values in the precuneus and lingual gyrus/cerebellum lobule VI might be used as a potential biomarker to distinguish the patients from the FBC with a sensitivity of 96.43%, a specificity of 89.29%, and an accuracy of 92.86%.
7-1	960-967	However	_
7-2	968-969	,	_
7-3	970-973	SVM	_
7-4	974-982	analysis	_
7-5	983-992	indicated	_
7-6	993-997	that	_
7-7	998-999	a	_
7-8	1000-1011	combination	_
7-9	1012-1014	of	_
7-10	1015-1019	VMHC	_
7-11	1020-1026	values	_
7-12	1027-1029	in	_
7-13	1030-1033	the	_
7-14	1034-1043	precuneus	_
7-15	1044-1047	and	_
7-16	1048-1055	lingual	_
7-17	1056-1072	gyrus/cerebellum	_
7-18	1073-1079	lobule	_
7-19	1080-1082	VI	_
7-20	1083-1088	might	_
7-21	1089-1091	be	_
7-22	1092-1096	used	_
7-23	1097-1099	as	_
7-24	1100-1101	a	_
7-25	1102-1111	potential	_
7-26	1112-1121	biomarker	_
7-27	1122-1124	to	_
7-28	1125-1136	distinguish	_
7-29	1137-1140	the	_
7-30	1141-1149	patients	_
7-31	1150-1154	from	_
7-32	1155-1158	the	_
7-33	1159-1162	FBC	_
7-34	1163-1167	with	_
7-35	1168-1169	a	_
7-36	1170-1181	sensitivity	_
7-37	1182-1184	of	_
7-38	1185-1190	96.43	_
7-39	1191-1192	%	_
7-40	1193-1194	,	_
7-41	1195-1196	a	_
7-42	1197-1208	specificity	_
7-43	1209-1211	of	_
7-44	1212-1217	89.29	_
7-45	1218-1219	%	_
7-46	1220-1221	,	_
7-47	1222-1225	and	_
7-48	1226-1228	an	_
7-49	1229-1237	accuracy	_
7-50	1238-1240	of	_
7-51	1241-1246	92.86	_
7-52	1247-1248	%	_
7-53	1249-1250	.	_

Text=Results suggested that patients with schizophrenia have decreased homotopic connectivity in the motor and low level sensory processing regions.
8-1	1251-1258	Results	_
8-2	1259-1268	suggested	_
8-3	1269-1273	that	_
8-4	1274-1282	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-5	1283-1287	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-6	1288-1301	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-7	1302-1306	have	_
8-8	1307-1316	decreased	_
8-9	1317-1326	homotopic	_
8-10	1327-1339	connectivity	_
8-11	1340-1342	in	_
8-12	1343-1346	the	_
8-13	1347-1352	motor	_
8-14	1353-1356	and	_
8-15	1357-1360	low	_
8-16	1361-1366	level	_
8-17	1367-1374	sensory	_
8-18	1375-1385	processing	_
8-19	1386-1393	regions	_
8-20	1394-1395	.	_

Text=Neuroimaging studies can adopt family-based case-control design as a viable option to reduce the confounding effects of environmental factors on schizophrenia.
9-1	1396-1408	Neuroimaging	_
9-2	1409-1416	studies	_
9-3	1417-1420	can	_
9-4	1421-1426	adopt	_
9-5	1427-1439	family-based	_
9-6	1440-1452	case-control	_
9-7	1453-1459	design	_
9-8	1460-1462	as	_
9-9	1463-1464	a	_
9-10	1465-1471	viable	_
9-11	1472-1478	option	_
9-12	1479-1481	to	_
9-13	1482-1488	reduce	_
9-14	1489-1492	the	_
9-15	1493-1504	confounding	_
9-16	1505-1512	effects	_
9-17	1513-1515	of	_
9-18	1516-1529	environmental	_
9-19	1530-1537	factors	_
9-20	1538-1540	on	_
9-21	1541-1554	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-22	1555-1556	.	_

Text=Materials and Methods Participants This study was conducted in accordance with the Helsinki Declaration.
10-1	1557-1566	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1567-1570	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1571-1578	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1579-1591	Participants	_
10-5	1592-1596	This	_
10-6	1597-1602	study	_
10-7	1603-1606	was	_
10-8	1607-1616	conducted	_
10-9	1617-1619	in	_
10-10	1620-1630	accordance	_
10-11	1631-1635	with	_
10-12	1636-1639	the	_
10-13	1640-1648	Helsinki	_
10-14	1649-1660	Declaration	_
10-15	1661-1662	.	_

Text=Thirty right-handed patients were recruited from Mental Health Center of the First Affiliated Hospital, Guangxi Medical University in China.
11-1	1663-1669	Thirty	_
11-2	1670-1682	right-handed	_
11-3	1683-1691	patients	_
11-4	1692-1696	were	_
11-5	1697-1706	recruited	_
11-6	1707-1711	from	_
11-7	1712-1718	Mental	_
11-8	1719-1725	Health	_
11-9	1726-1732	Center	_
11-10	1733-1735	of	_
11-11	1736-1739	the	_
11-12	1740-1745	First	_
11-13	1746-1756	Affiliated	_
11-14	1757-1765	Hospital	_
11-15	1766-1767	,	_
11-16	1768-1775	Guangxi	_
11-17	1776-1783	Medical	_
11-18	1784-1794	University	_
11-19	1795-1797	in	_
11-20	1798-1803	China	_
11-21	1804-1805	.	_

Text=Clinical diagnosis was made in accordance with the Structured Clinical Interview of the DSM-IV (SCID).
12-1	1806-1814	Clinical	_
12-2	1815-1824	diagnosis	_
12-3	1825-1828	was	_
12-4	1829-1833	made	_
12-5	1834-1836	in	_
12-6	1837-1847	accordance	_
12-7	1848-1852	with	_
12-8	1853-1856	the	_
12-9	1857-1867	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-10	1868-1876	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-11	1877-1886	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-12	1887-1889	of	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-13	1890-1893	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-14	1894-1900	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-15	1901-1902	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-16	1903-1907	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-17	1908-1909	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-18	1910-1911	.	_

Text=To reduce the heterogeneity of symptom manifestations, only patients with paranoid schizophrenia were enrolled.
13-1	1912-1914	To	_
13-2	1915-1921	reduce	_
13-3	1922-1925	the	_
13-4	1926-1939	heterogeneity	_
13-5	1940-1942	of	_
13-6	1943-1950	symptom	_
13-7	1951-1965	manifestations	_
13-8	1966-1967	,	_
13-9	1968-1972	only	_
13-10	1973-1981	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-11	1982-1986	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-12	1987-1995	paranoid	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-13	1996-2009	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-14	2010-2014	were	_
13-15	2015-2023	enrolled	_
13-16	2024-2025	.	_

Text=The patients, who aged from 18 to 30 years old with more than 9 years of education, were first-episode and drug-naive at the scan time.
14-1	2026-2029	The	_
14-2	2030-2038	patients	_
14-3	2039-2040	,	_
14-4	2041-2044	who	_
14-5	2045-2049	aged	_
14-6	2050-2054	from	_
14-7	2055-2057	18	_
14-8	2058-2060	to	_
14-9	2061-2063	30	_
14-10	2064-2069	years	_
14-11	2070-2073	old	_
14-12	2074-2078	with	_
14-13	2079-2083	more	_
14-14	2084-2088	than	_
14-15	2089-2090	9	_
14-16	2091-2096	years	_
14-17	2097-2099	of	_
14-18	2100-2109	education	_
14-19	2110-2111	,	_
14-20	2112-2116	were	_
14-21	2117-2130	first-episode	_
14-22	2131-2134	and	_
14-23	2135-2145	drug-naive	_
14-24	2146-2148	at	_
14-25	2149-2152	the	_
14-26	2153-2157	scan	_
14-27	2158-2162	time	_
14-28	2163-2164	.	_

Text=The illness duration was less than 3 years.
15-1	2165-2168	The	_
15-2	2169-2176	illness	_
15-3	2177-2185	duration	_
15-4	2186-2189	was	_
15-5	2190-2194	less	_
15-6	2195-2199	than	_
15-7	2200-2201	3	_
15-8	2202-2207	years	_
15-9	2208-2209	.	_

Text=Patients who had neurological disorders, severe medical disorders, substance abuse, or electroconvulsive therapy were excluded.
16-1	2210-2218	Patients	_
16-2	2219-2222	who	_
16-3	2223-2226	had	_
16-4	2227-2239	neurological	_
16-5	2240-2249	disorders	_
16-6	2250-2251	,	_
16-7	2252-2258	severe	_
16-8	2259-2266	medical	_
16-9	2267-2276	disorders	_
16-10	2277-2278	,	_
16-11	2279-2288	substance	_
16-12	2289-2294	abuse	_
16-13	2295-2296	,	_
16-14	2297-2299	or	_
16-15	2300-2317	electroconvulsive	_
16-16	2318-2325	therapy	_
16-17	2326-2330	were	_
16-18	2331-2339	excluded	_
16-19	2340-2341	.	_

Text=Symptom severity was rated using the Positive and Negative Symptom Scale (PANSS).
17-1	2342-2349	Symptom	_
17-2	2350-2358	severity	_
17-3	2359-2362	was	_
17-4	2363-2368	rated	_
17-5	2369-2374	using	_
17-6	2375-2378	the	_
17-7	2379-2387	Positive	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-8	2388-2391	and	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-9	2392-2400	Negative	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-10	2401-2408	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-11	2409-2414	Scale	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-12	2415-2416	(	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-13	2417-2422	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-14	2423-2424	)	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
17-15	2425-2426	.	_

Text=Thirty right-handed unaffected siblings of the patients were recruited as the FBC.
18-1	2427-2433	Thirty	_
18-2	2434-2446	right-handed	_
18-3	2447-2457	unaffected	_
18-4	2458-2466	siblings	_
18-5	2467-2469	of	_
18-6	2470-2473	the	_
18-7	2474-2482	patients	_
18-8	2483-2487	were	_
18-9	2488-2497	recruited	_
18-10	2498-2500	as	_
18-11	2501-2504	the	_
18-12	2505-2508	FBC	http://maven.renci.org/NeuroBridge/neurobridge#Thing
18-13	2509-2510	.	_

Text=Each patient was matched with one sibling from the same family.
19-1	2511-2515	Each	_
19-2	2516-2523	patient	_
19-3	2524-2527	was	_
19-4	2528-2535	matched	_
19-5	2536-2540	with	_
19-6	2541-2544	one	_
19-7	2545-2552	sibling	_
19-8	2553-2557	from	_
19-9	2558-2561	the	_
19-10	2562-2566	same	_
19-11	2567-2573	family	_
19-12	2574-2575	.	_

Text=Forty-two right-handed HC were recruited from the community.
20-1	2576-2585	Forty-two	_
20-2	2586-2598	right-handed	_
20-3	2599-2601	HC	_
20-4	2602-2606	were	_
20-5	2607-2616	recruited	_
20-6	2617-2621	from	_
20-7	2622-2625	the	_
20-8	2626-2635	community	_
20-9	2636-2637	.	_

Text=The FBC and the HC were screened by SCID, non-patient edition.
21-1	2638-2641	The	_
21-2	2642-2645	FBC	http://maven.renci.org/NeuroBridge/neurobridge#Thing
21-3	2646-2649	and	_
21-4	2650-2653	the	_
21-5	2654-2656	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
21-6	2657-2661	were	_
21-7	2662-2670	screened	_
21-8	2671-2673	by	_
21-9	2674-2678	SCID	_
21-10	2679-2680	,	_
21-11	2681-2692	non-patient	_
21-12	2693-2700	edition	_
21-13	2701-2702	.	_

Text=The age of the controls ranged from 18 to 30 years, and their education level was more than 9 years.
22-1	2703-2706	The	_
22-2	2707-2710	age	_
22-3	2711-2713	of	_
22-4	2714-2717	the	_
22-5	2718-2726	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
22-6	2727-2733	ranged	_
22-7	2734-2738	from	_
22-8	2739-2741	18	_
22-9	2742-2744	to	_
22-10	2745-2747	30	_
22-11	2748-2753	years	_
22-12	2754-2755	,	_
22-13	2756-2759	and	_
22-14	2760-2765	their	_
22-15	2766-2775	education	_
22-16	2776-2781	level	_
22-17	2782-2785	was	_
22-18	2786-2790	more	_
22-19	2791-2795	than	_
22-20	2796-2797	9	_
22-21	2798-2803	years	_
22-22	2804-2805	.	_

Text=None of the controls had any neurological disorders, severe medical disorders, substance abuse or psychiatric disorders.
23-1	2806-2810	None	_
23-2	2811-2813	of	_
23-3	2814-2817	the	_
23-4	2818-2826	controls	_
23-5	2827-2830	had	_
23-6	2831-2834	any	_
23-7	2835-2847	neurological	_
23-8	2848-2857	disorders	_
23-9	2858-2859	,	_
23-10	2860-2866	severe	_
23-11	2867-2874	medical	_
23-12	2875-2884	disorders	_
23-13	2885-2886	,	_
23-14	2887-2896	substance	_
23-15	2897-2902	abuse	_
23-16	2903-2905	or	_
23-17	2906-2917	psychiatric	_
23-18	2918-2927	disorders	_
23-19	2928-2929	.	_

Text=Written informed consent was acquired from each participant prior to data collection.
24-1	2930-2937	Written	_
24-2	2938-2946	informed	_
24-3	2947-2954	consent	_
24-4	2955-2958	was	_
24-5	2959-2967	acquired	_
24-6	2968-2972	from	_
24-7	2973-2977	each	_
24-8	2978-2989	participant	_
24-9	2990-2995	prior	_
24-10	2996-2998	to	_
24-11	2999-3003	data	_
24-12	3004-3014	collection	_
24-13	3015-3016	.	_

Text=This study was approved by the local ethics committee of the First Affiliated Hospital, Guangxi Medical University.
25-1	3017-3021	This	_
25-2	3022-3027	study	_
25-3	3028-3031	was	_
25-4	3032-3040	approved	_
25-5	3041-3043	by	_
25-6	3044-3047	the	_
25-7	3048-3053	local	_
25-8	3054-3060	ethics	_
25-9	3061-3070	committee	_
25-10	3071-3073	of	_
25-11	3074-3077	the	_
25-12	3078-3083	First	_
25-13	3084-3094	Affiliated	_
25-14	3095-3103	Hospital	_
25-15	3104-3105	,	_
25-16	3106-3113	Guangxi	_
25-17	3114-3121	Medical	_
25-18	3122-3132	University	_
25-19	3133-3134	.	_

Text=Data acquisition and preprocessing MRI images were obtained on a Siemens (Trio) 3T scanner.
26-1	3135-3139	Data	_
26-2	3140-3151	acquisition	_
26-3	3152-3155	and	_
26-4	3156-3169	preprocessing	_
26-5	3170-3173	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
26-6	3174-3180	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
26-7	3181-3185	were	_
26-8	3186-3194	obtained	_
26-9	3195-3197	on	_
26-10	3198-3199	a	_
26-11	3200-3207	Siemens	_
26-12	3208-3209	(	_
26-13	3210-3214	Trio	_
26-14	3215-3216	)	_
26-15	3217-3219	3T	_
26-16	3220-3227	scanner	_
26-17	3228-3229	.	_

Text=Data Processing Assistant for Resting-State fMRI (DPARSF) software (version 2.3) was applied to preprocess the images.
27-1	3230-3234	Data	_
27-2	3235-3245	Processing	_
27-3	3246-3255	Assistant	_
27-4	3256-3259	for	_
27-5	3260-3273	Resting-State	_
27-6	3274-3278	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
27-7	3279-3280	(	_
27-8	3281-3287	DPARSF	_
27-9	3288-3289	)	_
27-10	3290-3298	software	_
27-11	3299-3300	(	_
27-12	3301-3308	version	_
27-13	3309-3312	2.3	_
27-14	3313-3314	)	_
27-15	3315-3318	was	_
27-16	3319-3326	applied	_
27-17	3327-3329	to	_
27-18	3330-3340	preprocess	_
27-19	3341-3344	the	_
27-20	3345-3351	images	_
27-21	3352-3353	.	_

Text=Details on data acquisition and preprocessing were provided in Supplementary files.
28-1	3354-3361	Details	_
28-2	3362-3364	on	_
28-3	3365-3369	data	_
28-4	3370-3381	acquisition	_
28-5	3382-3385	and	_
28-6	3386-3399	preprocessing	_
28-7	3400-3404	were	_
28-8	3405-3413	provided	_
28-9	3414-3416	in	_
28-10	3417-3430	Supplementary	_
28-11	3431-3436	files	_
28-12	3437-3438	.	_

Text=VMHC analysis VMHC analysis was conducted with the REST software (version 1.8).
29-1	3439-3443	VMHC	_
29-2	3444-3452	analysis	_
29-3	3453-3457	VMHC	_
29-4	3458-3466	analysis	_
29-5	3467-3470	was	_
29-6	3471-3480	conducted	_
29-7	3481-3485	with	_
29-8	3486-3489	the	_
29-9	3490-3494	REST	_
29-10	3495-3503	software	_
29-11	3504-3505	(	_
29-12	3506-3513	version	_
29-13	3514-3517	1.8	_
29-14	3518-3519	)	_
29-15	3520-3521	.	_

Text=For each participant, homotopic FC was calculated as the Pearson correlation coefficient between each voxel ’ s residual time series and that of its interhemispheric mirrored voxel.
30-1	3522-3525	For	_
30-2	3526-3530	each	_
30-3	3531-3542	participant	_
30-4	3543-3544	,	_
30-5	3545-3554	homotopic	_
30-6	3555-3557	FC	_
30-7	3558-3561	was	_
30-8	3562-3572	calculated	_
30-9	3573-3575	as	_
30-10	3576-3579	the	_
30-11	3580-3587	Pearson	_
30-12	3588-3599	correlation	_
30-13	3600-3611	coefficient	_
30-14	3612-3619	between	_
30-15	3620-3624	each	_
30-16	3625-3630	voxel	_
30-17	3631-3632	’	_
30-18	3633-3634	s	_
30-19	3635-3643	residual	_
30-20	3644-3648	time	_
30-21	3649-3655	series	_
30-22	3656-3659	and	_
30-23	3660-3664	that	_
30-24	3665-3667	of	_
30-25	3668-3671	its	_
30-26	3672-3688	interhemispheric	_
30-27	3689-3697	mirrored	_
30-28	3698-3703	voxel	_
30-29	3704-3705	.	_

Text=The coefficients were then Fisher z-transformed, and VMHC maps were generated for each participant.
31-1	3706-3709	The	_
31-2	3710-3722	coefficients	_
31-3	3723-3727	were	_
31-4	3728-3732	then	_
31-5	3733-3739	Fisher	_
31-6	3740-3753	z-transformed	_
31-7	3754-3755	,	_
31-8	3756-3759	and	_
31-9	3760-3764	VMHC	_
31-10	3765-3769	maps	_
31-11	3770-3774	were	_
31-12	3775-3784	generated	_
31-13	3785-3788	for	_
31-14	3789-3793	each	_
31-15	3794-3805	participant	_
31-16	3806-3807	.	_

Text=For each group, one-sample t-tests were applied to identify voxels that exhibited significant correlations with their mirrored counterparts.
32-1	3808-3811	For	_
32-2	3812-3816	each	_
32-3	3817-3822	group	_
32-4	3823-3824	,	_
32-5	3825-3835	one-sample	_
32-6	3836-3843	t-tests	_
32-7	3844-3848	were	_
32-8	3849-3856	applied	_
32-9	3857-3859	to	_
32-10	3860-3868	identify	_
32-11	3869-3875	voxels	_
32-12	3876-3880	that	_
32-13	3881-3890	exhibited	_
32-14	3891-3902	significant	_
32-15	3903-3915	correlations	_
32-16	3916-3920	with	_
32-17	3921-3926	their	_
32-18	3927-3935	mirrored	_
32-19	3936-3948	counterparts	_
32-20	3949-3950	.	_

Text=The significance level was set at p <0.05 for multiple comparisons corrected by Gaussian Random Field (GRF) theory (voxel significance: p <0.001, cluster significance: p <0.05).
33-1	3951-3954	The	_
33-2	3955-3967	significance	_
33-3	3968-3973	level	_
33-4	3974-3977	was	_
33-5	3978-3981	set	_
33-6	3982-3984	at	_
33-7	3985-3986	p	_
33-8	3987-3988	<	_
33-9	3989-3993	0.05	_
33-10	3994-3997	for	_
33-11	3998-4006	multiple	_
33-12	4007-4018	comparisons	_
33-13	4019-4028	corrected	_
33-14	4029-4031	by	_
33-15	4032-4040	Gaussian	_
33-16	4041-4047	Random	_
33-17	4048-4053	Field	_
33-18	4054-4055	(	_
33-19	4056-4059	GRF	_
33-20	4060-4061	)	_
33-21	4062-4068	theory	_
33-22	4069-4070	(	_
33-23	4071-4076	voxel	_
33-24	4077-4089	significance	_
33-25	4090-4091	:	_
33-26	4092-4093	p	_
33-27	4094-4095	<	_
33-28	4096-4101	0.001	_
33-29	4102-4103	,	_
33-30	4104-4111	cluster	_
33-31	4112-4124	significance	_
33-32	4125-4126	:	_
33-33	4127-4128	p	_
33-34	4129-4130	<	_
33-35	4131-4135	0.05	_
33-36	4136-4137	)	_
33-37	4138-4139	.	_

Text=Analyses of covariance (ANCOVA), followed by post hoc t-tests (paired-sample t-tests were used to compare group differences between the patients and the FBC), were performed to compare group differences within the union mask of one-sample t-tests of the three groups.
34-1	4140-4148	Analyses	_
34-2	4149-4151	of	_
34-3	4152-4162	covariance	_
34-4	4163-4164	(	_
34-5	4165-4171	ANCOVA	_
34-6	4172-4173	)	_
34-7	4174-4175	,	_
34-8	4176-4184	followed	_
34-9	4185-4187	by	_
34-10	4188-4192	post	_
34-11	4193-4196	hoc	_
34-12	4197-4204	t-tests	_
34-13	4205-4206	(	_
34-14	4207-4220	paired-sample	_
34-15	4221-4228	t-tests	_
34-16	4229-4233	were	_
34-17	4234-4238	used	_
34-18	4239-4241	to	_
34-19	4242-4249	compare	_
34-20	4250-4255	group	_
34-21	4256-4267	differences	_
34-22	4268-4275	between	_
34-23	4276-4279	the	_
34-24	4280-4288	patients	_
34-25	4289-4292	and	_
34-26	4293-4296	the	_
34-27	4297-4300	FBC	_
34-28	4301-4302	)	_
34-29	4303-4304	,	_
34-30	4305-4309	were	_
34-31	4310-4319	performed	_
34-32	4320-4322	to	_
34-33	4323-4330	compare	_
34-34	4331-4336	group	_
34-35	4337-4348	differences	_
34-36	4349-4355	within	_
34-37	4356-4359	the	_
34-38	4360-4365	union	_
34-39	4366-4370	mask	_
34-40	4371-4373	of	_
34-41	4374-4384	one-sample	_
34-42	4385-4392	t-tests	_
34-43	4393-4395	of	_
34-44	4396-4399	the	_
34-45	4400-4405	three	_
34-46	4406-4412	groups	_
34-47	4413-4414	.	_

Text=Age and years of education were used as covariates to minimize the potential effects of these variables.
35-1	4415-4418	Age	_
35-2	4419-4422	and	_
35-3	4423-4428	years	_
35-4	4429-4431	of	_
35-5	4432-4441	education	_
35-6	4442-4446	were	_
35-7	4447-4451	used	_
35-8	4452-4454	as	_
35-9	4455-4465	covariates	_
35-10	4466-4468	to	_
35-11	4469-4477	minimize	_
35-12	4478-4481	the	_
35-13	4482-4491	potential	_
35-14	4492-4499	effects	_
35-15	4500-4502	of	_
35-16	4503-4508	these	_
35-17	4509-4518	variables	_
35-18	4519-4520	.	_

Text=Framewise displacement (FD) values were computed for each participant as described in a previous study, and FD was used as a covariate in the group comparisons.
36-1	4521-4530	Framewise	_
36-2	4531-4543	displacement	_
36-3	4544-4545	(	_
36-4	4546-4548	FD	_
36-5	4549-4550	)	_
36-6	4551-4557	values	_
36-7	4558-4562	were	_
36-8	4563-4571	computed	_
36-9	4572-4575	for	_
36-10	4576-4580	each	_
36-11	4581-4592	participant	_
36-12	4593-4595	as	_
36-13	4596-4605	described	_
36-14	4606-4608	in	_
36-15	4609-4610	a	_
36-16	4611-4619	previous	_
36-17	4620-4625	study	_
36-18	4626-4627	,	_
36-19	4628-4631	and	_
36-20	4632-4634	FD	_
36-21	4635-4638	was	_
36-22	4639-4643	used	_
36-23	4644-4646	as	_
36-24	4647-4648	a	_
36-25	4649-4658	covariate	_
36-26	4659-4661	in	_
36-27	4662-4665	the	_
36-28	4666-4671	group	_
36-29	4672-4683	comparisons	_
36-30	4684-4685	.	_

Text=The significance level was set at p <0.05 (GRF corrected).
37-1	4686-4689	The	_
37-2	4690-4702	significance	_
37-3	4703-4708	level	_
37-4	4709-4712	was	_
37-5	4713-4716	set	_
37-6	4717-4719	at	_
37-7	4720-4721	p	_
37-8	4722-4723	<	_
37-9	4724-4728	0.05	_
37-10	4729-4730	(	_
37-11	4731-4734	GRF	_
37-12	4735-4744	corrected	_
37-13	4745-4746	)	_
37-14	4747-4748	.	_

Text=Correlation analysis Once significant group differences were found in any brain regions, the mean z values of these brain regions were extracted to assess the correlations between abnormal VMHC values and symptom severity in the patients.
38-1	4749-4760	Correlation	_
38-2	4761-4769	analysis	_
38-3	4770-4774	Once	_
38-4	4775-4786	significant	_
38-5	4787-4792	group	_
38-6	4793-4804	differences	_
38-7	4805-4809	were	_
38-8	4810-4815	found	_
38-9	4816-4818	in	_
38-10	4819-4822	any	_
38-11	4823-4828	brain	_
38-12	4829-4836	regions	_
38-13	4837-4838	,	_
38-14	4839-4842	the	_
38-15	4843-4847	mean	_
38-16	4848-4849	z	_
38-17	4850-4856	values	_
38-18	4857-4859	of	_
38-19	4860-4865	these	_
38-20	4866-4871	brain	_
38-21	4872-4879	regions	_
38-22	4880-4884	were	_
38-23	4885-4894	extracted	_
38-24	4895-4897	to	_
38-25	4898-4904	assess	_
38-26	4905-4908	the	_
38-27	4909-4921	correlations	_
38-28	4922-4929	between	_
38-29	4930-4938	abnormal	_
38-30	4939-4943	VMHC	_
38-31	4944-4950	values	_
38-32	4951-4954	and	_
38-33	4955-4962	symptom	_
38-34	4963-4971	severity	_
38-35	4972-4974	in	_
38-36	4975-4978	the	_
38-37	4979-4987	patients	_
38-38	4988-4989	.	_

Text=The correlation results were Bonferroni corrected at p <0.05.
39-1	4990-4993	The	_
39-2	4994-5005	correlation	_
39-3	5006-5013	results	_
39-4	5014-5018	were	_
39-5	5019-5029	Bonferroni	_
39-6	5030-5039	corrected	_
39-7	5040-5042	at	_
39-8	5043-5044	p	_
39-9	5045-5046	<	_
39-10	5047-5051	0.05	_
39-11	5052-5053	.	_

Text=To determine whether abnormal VMHC values were correlated in the patients and the FBC, we made a mask on the deficit clusters of the VMHC results between the patients and the FBC.
40-1	5054-5056	To	_
40-2	5057-5066	determine	_
40-3	5067-5074	whether	_
40-4	5075-5083	abnormal	_
40-5	5084-5088	VMHC	_
40-6	5089-5095	values	_
40-7	5096-5100	were	_
40-8	5101-5111	correlated	_
40-9	5112-5114	in	_
40-10	5115-5118	the	_
40-11	5119-5127	patients	_
40-12	5128-5131	and	_
40-13	5132-5135	the	_
40-14	5136-5139	FBC	_
40-15	5140-5141	,	_
40-16	5142-5144	we	_
40-17	5145-5149	made	_
40-18	5150-5151	a	_
40-19	5152-5156	mask	_
40-20	5157-5159	on	_
40-21	5160-5163	the	_
40-22	5164-5171	deficit	_
40-23	5172-5180	clusters	_
40-24	5181-5183	of	_
40-25	5184-5187	the	_
40-26	5188-5192	VMHC	_
40-27	5193-5200	results	_
40-28	5201-5208	between	_
40-29	5209-5212	the	_
40-30	5213-5221	patients	_
40-31	5222-5225	and	_
40-32	5226-5229	the	_
40-33	5230-5233	FBC	_
40-34	5234-5235	.	_

Text=Then, the mean z values within the mask were extracted in the patients and the FBC.
41-1	5236-5240	Then	_
41-2	5241-5242	,	_
41-3	5243-5246	the	_
41-4	5247-5251	mean	_
41-5	5252-5253	z	_
41-6	5254-5260	values	_
41-7	5261-5267	within	_
41-8	5268-5271	the	_
41-9	5272-5276	mask	_
41-10	5277-5281	were	_
41-11	5282-5291	extracted	_
41-12	5292-5294	in	_
41-13	5295-5298	the	_
41-14	5299-5307	patients	_
41-15	5308-5311	and	_
41-16	5312-5315	the	_
41-17	5316-5319	FBC	_
41-18	5320-5321	.	_

Text=Finally, Pearson correlation analysis was performed on the abnormal VMHC values between the patients and the FBC.
42-1	5322-5329	Finally	_
42-2	5330-5331	,	_
42-3	5332-5339	Pearson	_
42-4	5340-5351	correlation	_
42-5	5352-5360	analysis	_
42-6	5361-5364	was	_
42-7	5365-5374	performed	_
42-8	5375-5377	on	_
42-9	5378-5381	the	_
42-10	5382-5390	abnormal	_
42-11	5391-5395	VMHC	_
42-12	5396-5402	values	_
42-13	5403-5410	between	_
42-14	5411-5414	the	_
42-15	5415-5423	patients	_
42-16	5424-5427	and	_
42-17	5428-5431	the	_
42-18	5432-5435	FBC	_
42-19	5436-5437	.	_

Text=In addition, the correlations between abnormal VMHC values for each cluster were computed between the patients and the FBC.
43-1	5438-5440	In	_
43-2	5441-5449	addition	_
43-3	5450-5451	,	_
43-4	5452-5455	the	_
43-5	5456-5468	correlations	_
43-6	5469-5476	between	_
43-7	5477-5485	abnormal	_
43-8	5486-5490	VMHC	_
43-9	5491-5497	values	_
43-10	5498-5501	for	_
43-11	5502-5506	each	_
43-12	5507-5514	cluster	_
43-13	5515-5519	were	_
43-14	5520-5528	computed	_
43-15	5529-5536	between	_
43-16	5537-5540	the	_
43-17	5541-5549	patients	_
43-18	5550-5553	and	_
43-19	5554-5557	the	_
43-20	5558-5561	FBC	_
43-21	5562-5563	.	_

Text=Receiver operating characteristic curve (ROC) analysis and support vector machine (SVM) analysis using LIBSVM ROC analysis was conducted to determine whether VMHC in the brain regions with group differences can differentiate the patients from the controls.
44-1	5564-5572	Receiver	_
44-2	5573-5582	operating	_
44-3	5583-5597	characteristic	_
44-4	5598-5603	curve	_
44-5	5604-5605	(	_
44-6	5606-5609	ROC	_
44-7	5610-5611	)	_
44-8	5612-5620	analysis	_
44-9	5621-5624	and	_
44-10	5625-5632	support	_
44-11	5633-5639	vector	_
44-12	5640-5647	machine	_
44-13	5648-5649	(	_
44-14	5650-5653	SVM	_
44-15	5654-5655	)	_
44-16	5656-5664	analysis	_
44-17	5665-5670	using	_
44-18	5671-5677	LIBSVM	_
44-19	5678-5681	ROC	_
44-20	5682-5690	analysis	_
44-21	5691-5694	was	_
44-22	5695-5704	conducted	_
44-23	5705-5707	to	_
44-24	5708-5717	determine	_
44-25	5718-5725	whether	_
44-26	5726-5730	VMHC	_
44-27	5731-5733	in	_
44-28	5734-5737	the	_
44-29	5738-5743	brain	_
44-30	5744-5751	regions	_
44-31	5752-5756	with	_
44-32	5757-5762	group	_
44-33	5763-5774	differences	_
44-34	5775-5778	can	_
44-35	5779-5792	differentiate	_
44-36	5793-5796	the	_
44-37	5797-5805	patients	_
44-38	5806-5810	from	_
44-39	5811-5814	the	_
44-40	5815-5823	controls	_
44-41	5824-5825	.	_

Text=The LIBSVM software package (http: //www.csie.ntu.edu.tw/~cjlin/libsvm/) in Matlab was applied to explore the possibility of combining these clusters to distinguish the patients from the HC/FBC.
45-1	5826-5829	The	_
45-2	5830-5836	LIBSVM	_
45-3	5837-5845	software	_
45-4	5846-5853	package	_
45-5	5854-5855	(	_
45-6	5856-5860	http	_
45-7	5861-5862	:	_
45-8	5863-5899	//www.csie.ntu.edu.tw/~cjlin/libsvm/	_
45-9	5900-5901	)	_
45-10	5902-5904	in	_
45-11	5905-5911	Matlab	_
45-12	5912-5915	was	_
45-13	5916-5923	applied	_
45-14	5924-5926	to	_
45-15	5927-5934	explore	_
45-16	5935-5938	the	_
45-17	5939-5950	possibility	_
45-18	5951-5953	of	_
45-19	5954-5963	combining	_
45-20	5964-5969	these	_
45-21	5970-5978	clusters	_
45-22	5979-5981	to	_
45-23	5982-5993	distinguish	_
45-24	5994-5997	the	_
45-25	5998-6006	patients	_
45-26	6007-6011	from	_
45-27	6012-6015	the	_
45-28	6016-6022	HC/FBC	_
45-29	6023-6024	.	_

Text=The Grid search method and Gaussian radial basis function kernels were used for parameter optimization.
46-1	6025-6028	The	_
46-2	6029-6033	Grid	_
46-3	6034-6040	search	_
46-4	6041-6047	method	_
46-5	6048-6051	and	_
46-6	6052-6060	Gaussian	_
46-7	6061-6067	radial	_
46-8	6068-6073	basis	_
46-9	6074-6082	function	_
46-10	6083-6090	kernels	_
46-11	6091-6095	were	_
46-12	6096-6100	used	_
46-13	6101-6104	for	_
46-14	6105-6114	parameter	_
46-15	6115-6127	optimization	_
46-16	6128-6129	.	_

Text=The “ leave-one-out ” cross-validation method was applied to obtain the highest sensitivity and specificity.
47-1	6130-6133	The	_
47-2	6134-6135	“	_
47-3	6136-6149	leave-one-out	_
47-4	6150-6151	”	_
47-5	6152-6168	cross-validation	_
47-6	6169-6175	method	_
47-7	6176-6179	was	_
47-8	6180-6187	applied	_
47-9	6188-6190	to	_
47-10	6191-6197	obtain	_
47-11	6198-6201	the	_
47-12	6202-6209	highest	_
47-13	6210-6221	sensitivity	_
47-14	6222-6225	and	_
47-15	6226-6237	specificity	_
47-16	6238-6239	.	_

